Lumexa Imaging Holdings, Inc. (LMRI) company profile
Close on Nov 17, 2026Market cap $1.41BP/E –Yield –
About Lumexa Imaging
Services-Medical Laboratories, SIC 8071
Lumexa Imaging Holdings, Inc. provides diagnostic imaging services in the United States. The company offers a range of advanced and routine medical imaging modalities, including magnetic resonance imaging, computed tomography, positron emission tomography, x-rays, ultrasound, and mammography. It also operates Connexia, an internal teleradiology platform that transmits radiographic images to remote, subspecialized radiologists for clinical interpretation. Lumexa Imaging delivers these diagnostic procedures to patients who require screening and diagnostic evaluations, serving individuals referred by affiliated healthcare providers, independent medical practices, and health system partners.
The company is headquartered in Raleigh, North Carolina. Lumexa Imaging operates 188 outpatient imaging centers located across 13 U.S. states, including eight joint venture partnerships with regional health systems. Its clinical network is supported by approximately 350 employed radiologists alongside contracts with over 890 radiologists in independent medical groups, handling patient referrals across tens of thousands of physician practices nationwide.
Summary of the business section of Lumexa Imaging's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lumexa Imaging Holdings, Inc.
- Founded
- 2018
- Headquarters
- Raleigh, NC
- Address
- 4200 Six Forks Road, Suite 1000 27609
- Phone
- (704) 334-7830
- Website
- lumexaimaging.com
- Industry
- Services-Medical Laboratories
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- LMRI
- Exchange
- Nasdaq
- IPO date
- Dec 12, 2025
- Shares outstanding
- 96M, Aug 12, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2071288
- CUSIP
- 550249106
- ISIN
- US5502491062
- FIGI
- BBG01YLK99T6
- Share class FIGI
- BBG01YLK9BQ4
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Caitlin Zulla | Chief Executive Officer, Director | 129,728 |
| James Edward Walker Jr. | Principal Accounting Officer | 17,346 |
| James Anthony Martin | Chief Financial Officer | 54,054 |
| Russell Stewart | Chief Medical Officer | 4,232 |
| Julie Szeker | Chief Legal Officer & Corp Sec | 66,182 |
| Bridget E. Karlin | Director | 19,358 |
| Glenn A. Eisenberg | Director | 19,358 |
| Molly Joseph | Director | 46,385 |
| Henry Lee Cooper | Director | 49,358 |
| Robert Louis Mittl Jr. | Director | 19,358 |
| Brett Brodnax | Director | 81,385 |
| Matthew Lungren | Director | 19,358 |
| Brian Thomas Regan | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Caitlin Zulla Chief Executive Officer | $750.00K | $3.50M | $5.43M | $9.02M | $750.00K | – | $19.47M | – |
| Tony Martin Chief Financial Officer | $590.00K | – | $2.43M | $4.21M | $590.00K | – | $7.84M | – |
| Julie Szeker Former Chief Legal Officer and Corporate Secretary | $450.00K | $1.75M | $2.10M | $663.47K | – | $15.51K | $5.00M | +703% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 12, 2025
- Securities offered
- 25,000,000
- Exchange
- Nasdaq
- First trading day
- Dec 11, 2025
- First-day close
- $18.52
- Lock-up ends (est.)
- Jun 9, 2026
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 12, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 11, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?